The analysis highlights Regeneron's robust Q2 2026 performance, with record sales for Dupixent, EYLEA HD, and Libtayo, and a significant beat on earnings estimates. The company also expanded its pipeline in July 2026 through a collaboration with Telix Pharmaceuticals for cancer therapies. In contrast, Novo Nordisk, a Danish pharmaceutical company, faces headwinds from intensifying competition in the GLP-1 market, U.S. government pricing pressure, and reduced Medicaid coverage for obesity drugs, despite strong performance from its Wegovy pill. For FY 2025, Novo Nordisk reported revenue of $47.7 billion (up 6.4%) and net income of $15.8 billion, while Regeneron reported revenue of $14.3 billion (up 1%) and net income of $4.5 billion.